New Novartis data presented at AAD reveals Cosentyx® is superior to Stelara® in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks(1)

Cosentyx® delivered and sustained skin clearance (PASI 90) in nearly 8 out of 10 moderate-to-severe psoriasis patients after 52 weeks of treatment1

DORVAL, QC, March 7, 2016 /CNW/ – Novartis presented new data from the head-to-head CLEAR study demonstrating that Cosentyx®…